At the Daiichi Sankyo Group, our mission is "to contribute to the enrichment of quality of life around the world through the creation of innovative pharmaceuticals, and through the provision of pharmaceuticals addressing diverse medical needs."

Seeking to accomplish this mission, the Daiichi Sankyo Group utilizes various internal capitals such as human capital, intellectual capital, financial capital, and social and relationship capital through partnerships and open innovation. With these resources, we are able to take advantage of the Company’s strengths in terms of science and technology, its global organization and talent, and strong presence in Japan in order to advance our business activities, thereby contributing to the evolution of society.

In terms of initiatives for resolving a multitude of challenges surrounding access to healthcare, we established the “Access to Healthcare” policy of Daiichi Sankyo Group, which is the pillar for activities such as the “promotion of research and development,” “improved access to pharmaceuticals,” and “reinforcement of regional medical infrastructures,” and have been working to addressing social issues through the Value Chain from research and development to manufacturing, sales and quality management & safety assurance activities.

PARTNERSHIPS

SHOWING 5 of 5 PARTNERSHIPS

See All

Access Accelerated Initiative

Tackling the growing burden of non-communicable diseases in low and middle-income countries and supporting...

Access Accelerated, Almirall, Astellas Pharma Inc, Bayer AG, Bristol-Myers Squibb, Celgene, Chiesi Farmaceutici, Chugai Pharmaceutical, Daiichi Sankyo, Eisai, Eli Lilly and Company, F. Hoffmann – La Roche Ltd., IFPMA, Johnson & Johnson, Menarini Group, Merck, MSD, Novartis Pharma AG, Pfizer Inc, Sanofi, Servier, Shionogi & Co., Ltd., Sumitomo Dainippon, Takeda Pharmaceutical Company Limited, UCB

SHOWING 5 of 5 PARTNERSHIPS

See All